Fludarabine/Cyclophosphamide/Rituxan is an effective regimen for non-myeloablative allogeneic stem cell transplantation (SCT) for lymphoid malignancies.

被引：0
|
作者：
Berkahn, LC [1 ]
Simpson, DR [1 ]
Raptis, A [1 ]
Klingemann, HG [1 ]
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5274
引用
收藏
页码：352B / 352B
页数：1
相关论文
共 50 条
  • [1] Fludarabine/cyclophosphamide non-myeloablative allogeneic stem cell transplantation for lymphoid malignancies
    Auer, R. L.
    MacDougall, F.
    Oakervee, H. E.
    Cavenagh, J. C.
    Gribben, J. G.
    Lister, T. A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 70 - 70
  • [2] Secondary allogeneic stem cell transplantation (alloSCT) using a non-myeloablative conditioning regimen for patients with hematological malignancies.
    Nagler, A
    Or, R
    Naparstek, E
    Varadi, G
    BenYosef, R
    Slavin, S
    BLOOD, 1998, 92 (10) : 137A - 137A
  • [3] Allogeneic Hematopoietic Stem Cell (HSC) grafting and non-myeloablative regimen in patients with hematological malignancies.
    Hansz, J
    Gozdzik, J
    Gil, L
    Drozdowska, D
    Kozlowska-Skrzypczak, M
    Sawinski, K
    BONE MARROW TRANSPLANTATION, 2001, 27 : S289 - S289
  • [4] Non-myeloablative hematopoietic stem cell transplantation for hematological malignancies.
    Yamane, T
    Aoyama, Y
    Hakamae, H
    Hasegawa, T
    Yamamura, R
    Sakamoto, C
    Terada, Y
    Koh, G
    Ohta, K
    Hino, M
    BLOOD, 2003, 102 (11) : 473B - 473B
  • [5] Non-myeloablative conditioning regimen for allogeneic stem cell transplantation in patients with advanced hematological malignancies
    Malesevic, M
    Stamatovic, D
    Tukic, L
    Marjanovic, S
    Balint, B
    Tarabar, O
    Todoric, B
    Ristic, L
    Milicevic, S
    BONE MARROW TRANSPLANTATION, 2001, 27 : S294 - S295
  • [6] ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) WITH NON-MYELOABLATIVE CONDITIONING FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SOLID TUMORS
    Novarino, A.
    Busca, A.
    Falda, M.
    Locatelli, F.
    Rossi, G.
    Galetto, A.
    Serra, A.
    Scaravaglio, P.
    Gallo, E.
    Ottaviani, D.
    Bertetto, O.
    ANNALS OF ONCOLOGY, 2004, 15 : 77 - 77
  • [7] Comparison of lymphoid and myeloid engraftment rates in patients receiving fludarabine/TBI or fludarabine/cyclophosphamide for non-myeloablative allogeneic transplantation
    Mellon-Reppen, S
    Dansey, R
    Abella, E
    Nehlsen-Cannarella, S
    Abidi, MH
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 50 - 50
  • [8] Fludarabine and treosulfan; a novel reduced-toxicity regimen for allogeneic stem cell transplantation (SCT) in patients with lymphoid malignancies
    Yerushalmi, R.
    Shem-Tov, N.
    Volchek, Y.
    Avigdor, A.
    Nagler, A.
    Shimoni, A.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S220 - S220
  • [9] Non-myeloablative regimen consisting of busulfan, fludarabine, and ATG for allogeneic peripheral blood stem cell transplantation.
    Mayer, J
    Koristek, Z
    Krahulová, M
    Vorlicek, J
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 131 - 131
  • [10] Comparison of lymphoid and myeloid engraftment rates in patients receiving fludarabine/TBI or fludarabine/cyclophosphamide for non-myeloablative allogeneic transplantation.
    Dansey, R
    Mellon-Reppen, S
    Nehlsen-Cannarella, S
    Klein, J
    Abidi, MH
    Abella, E
    BLOOD, 2003, 102 (11) : 438B - 438B
12345